MGI Aloxi Launch Set For September; Indications Include Delayed Nausea
Executive Summary
MGI Pharma plans to differentiate the antiemetic Aloxi (palonosetron) from other 5HT3 antagonists by highlighting a unique indication for delayed nausea in chemotherapy patients
You may also be interested in...
Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies
MGI Aloxi Oral Dose, Post-Operative Indications To Enter Phase III In 2004
MGI Pharma plans to commence Phase III trials for an oral formulation of the intravenous anti-emetic Aloxi (palonosetron), as well as studies supporting a post-operative indication
Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies